DEPO-MEDROL WITH LIDOCAINE 10 MG
LIDOCAINE HYDROCHLORIDE : 10 MG METHYLPREDNISOLONE ACETATE : 40 MG · DIN 00260428 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is DEPO-MEDROL WITH LIDOCAINE?
DEPO-MEDROL WITH LIDOCAINE 10 MG contains LIDOCAINE HYDROCHLORIDE : 10 MG METHYLPREDNISOLONE ACETATE : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 00260428, held by PFIZER CANADA ULC, supplied as SUSPENSION for PERIARTICULAR ; INTRASYNOVIAL ; INTRABURSAL ; INTRA-ARTICULAR administration. Health Canada currently lists it as marketed, status dated 20-May-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEPO-MEDROL WITH LIDOCAINE used for?
Short-term local adjunctive therapy for synovitis of osteoarthritis, rheumatoid arthritis, bursitis, acute gouty arthritis, epicondylitis, tenosynovitis, post-traumatic osteoarthritis, and ganglia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00260428 |
|---|---|
| Brand name | DEPO-MEDROL WITH LIDOCAINE |
| Generic / active ingredient | LIDOCAINE HYDROCHLORIDE : 10 MG METHYLPREDNISOLONE ACETATE : 40 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 10 MG |
| Dosage form | SUSPENSION |
| Route of administration | PERIARTICULAR ; INTRASYNOVIAL ; INTRABURSAL ; INTRA-ARTICULAR |
| Schedule | Prescription |
| ATC code | H02BX01 METHYLPREDNISOLONE, COMBINATIONS |
| AHFS class | 84:06.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-May-2022 |
| Original market date | 1973-12-31 00:00:00 |
How is it administered?
Intra-articular: Large joints 20-80mg; Medium 10-40mg; Small 4-10mg. Bursitis/Tendinitis: 4-30mg. Use strict aseptic technique. Do not dilute or mix with other solutions.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard USP range 3.5-7.0 pH mentioned for product stability).
How is it supplied?
1, 2 and 5 mL vials.
Contraindications
Hypersensitivity to components/amide anesthetics; systemic fungal infections; ITP (if IM); live vaccines; herpes simplex of eye; vaccinia/varicella; epidural/intravascular/intrathecal/IM use.
Warnings and precautions
Not for IV/epidural use. Risk of HPA suppression, infection masking, GI perforation, cardiovascular effects (edema, hypertension), and pheochromocytoma crisis. Contains benzyl alcohol.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.